Followers | 3819 |
Posts | 239216 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
Tuesday, November 29, 2016 4:28:31 PM
Shares of Genetic Technologies Ltd. (GENE) practically doubled in Tuesday’s session following a key licensing agreement. The company announced the signing of an exclusive worldwide license agreement with the University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.
Note that the terms and conditions of the agreement are confidential, but Genetic will be responsible for the commercial development of the test. Additionally, the University of Melbourne and Genetic will begin an ongoing research collaboration enabling the company to leverage the university's expertise in SNP-based risk assessment and risk model development.
The fundamental technology is similar to the BREVAGenplus test and should fit into the company's existing infrastructure and processes.
The CRC test represents a significant milestone for the company as it seeks to diversify its product pipeline and become a key player in the SNP-based cancer risk assessment landscape.
For some brief background: Excluding skin cancers, CRC is the third most common cancer diagnosed in both men and women in the United States. Overall, the lifetime risk for developing CRC is about one in 20. As with breast cancer, early diagnosis is key. When diagnosed at an early stage (before the disease has spread outside the colon), the relative five-year survival rate for CRC is 92% and 87% for rectal cancer, according to the American Cancer Society.
Related Quotes
GENE
2.14
+63.73% Genetic Technologies Limited? Watchlist
2.14+0.83(+63.73%)
NASDAQ4:00 PM EST
Genetic Technologies Practically Doubles on Licensing Agreement 24/7 Wall St. 4 hrs ago GENETIC TECHNOLOGIES LTD Financials EDGAR Online Financials 26 days ago MoreALSO READ: The Most Dangerous States in America
Eutillio Buccilli, executive director and CEO of Genetic Technologies, commented:
This is an exciting time for the Company as we commence this strategic alliance with The University of Melbourne. The relationship with the University is comprehensive and highlights our overall corporate mission to become a leader in the genomics focused oncology diagnostics' industry while enhancing our pipeline of risk assessment products.
Mark Jenkins, Professor of Epidemiology and Biostatistics at the University of Melbourne, added:
The licensing Agreement with Genetic Technologies provides us with a wonderful opportunity to work with an organisation that is a leader in the field of genomics for precision public health. Furthermore, Genetic Technologies provides the University with an established platform that will facilitate the transition of our scientific work into the clinical arena.
Shares of Genetic were trading up over 87% at $2.45 on Tuesday, with a consensus analyst price target of $12.50 and a 52-week trading range of $1.20 to $3.87.
Recent GENE News
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/22/2024 07:00:36 PM
- Genetic Technologies Announces $2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/18/2024 04:17:51 PM
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- GTG to pilot GeneType in Breast Screen centers across the U.S. • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk” • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market • GlobeNewswire Inc. • 04/02/2024 12:05:00 PM
- GTG Global Collaborations and Innovation Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:00:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 01:00:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:00:25 PM
- Launching our most comprehensive test and expanding into new global markets • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:00:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 01:00:16 PM
- Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/05/2024 05:15:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/28/2023 01:00:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 01:00:13 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/20/2023 10:00:51 PM
- GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment • GlobeNewswire Inc. • 10/18/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM